Inhibrx Biosciences, Inc. 8K

Inhibrx Biosciences, Inc. amended its loan agreement with Oxford Finance to add a new $100 million Term C tranche, provide for up to $225 million in discretionary Term D loans, update lender commitments, and pledge its equity in Poplar Therapeutics as additional collateral.

On July 15, 2026, Inhibrx Biosciences, Inc. entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance LLC, as collateral agent and lender, and various affiliated lending vehicles, to expand and reclassify its term loan facilities. The amendment confirms that the existing $100 million Term A Loans and $75 million Term B Loans have been fully funded, adds a new $100 million Term C Loan tranche available on the Second Amendment Date, and provides for an additional discretionary Term D Loan facility of up to $225 million that the lenders may, but are not obligated to, fund in one or more advances of at least $50 million each. The amendment also updates the definition of “Term Loan,” revises the lender commitment schedule to reflect aggregate commitments of $275 million, and requires the borrower contemporaneously to enter into a pledge agreement granting a security interest in all of its equity securities in Poplar Therapeutics as additional collateral, while otherwise ratifying and leaving in place the existing loan documentation and releasing the lenders from certain historical claims.

Filing Facts

CIK

2007919

Ticker

INBX

Form

8K

Source Type

fda

Accession

0002007919-26-000037

Alert Tier

7